 Kennon Heard
Concepts (647)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Acetaminophen | 40 | 2025 | 248 | 8.710 |
Why?
| | Chemical and Drug Induced Liver Injury | 15 | 2023 | 132 | 4.810 |
Why?
| | Analgesics, Non-Narcotic | 21 | 2025 | 122 | 4.620 |
Why?
| | Drug Overdose | 31 | 2025 | 326 | 4.270 |
Why?
| | Emergency Service, Hospital | 41 | 2023 | 1918 | 3.530 |
Why?
| | Poison Control Centers | 13 | 2025 | 88 | 3.500 |
Why?
| | Poisoning | 17 | 2017 | 111 | 3.060 |
Why?
| | Alanine Transaminase | 14 | 2023 | 154 | 2.620 |
Why?
| | Acetylcysteine | 11 | 2023 | 145 | 2.610 |
Why?
| | Cocaine | 10 | 2011 | 150 | 2.460 |
Why?
| | Cannabis | 9 | 2020 | 461 | 2.400 |
Why?
| | Prescription Drugs | 9 | 2018 | 109 | 2.260 |
Why?
| | Analgesics, Opioid | 8 | 2023 | 919 | 1.590 |
Why?
| | Antidotes | 9 | 2020 | 136 | 1.540 |
Why?
| | Legislation, Drug | 5 | 2017 | 77 | 1.500 |
Why?
| | Cysteine | 4 | 2017 | 195 | 1.380 |
Why?
| | Antipsychotic Agents | 7 | 2019 | 180 | 1.370 |
Why?
| | Marijuana Use | 4 | 2021 | 191 | 1.240 |
Why?
| | Medication Errors | 5 | 2015 | 96 | 1.170 |
Why?
| | Male | 103 | 2022 | 63586 | 1.170 |
Why?
| | Humans | 155 | 2025 | 129527 | 1.130 |
Why?
| | Emergency Medicine | 6 | 2019 | 217 | 1.120 |
Why?
| | Cocaine-Related Disorders | 5 | 2011 | 108 | 1.110 |
Why?
| | Toxicology | 4 | 2021 | 41 | 1.070 |
Why?
| | Drug Packaging | 2 | 2017 | 41 | 1.070 |
Why?
| | Pain | 9 | 2020 | 788 | 1.060 |
Why?
| | Female | 95 | 2022 | 68650 | 1.010 |
Why?
| | Adult | 73 | 2022 | 35505 | 1.000 |
Why?
| | Medication Reconciliation | 2 | 2016 | 29 | 0.970 |
Why?
| | Dose-Response Relationship, Drug | 16 | 2017 | 2013 | 0.950 |
Why?
| | Antidepressive Agents, Tricyclic | 5 | 2014 | 30 | 0.900 |
Why?
| | Spider Bites | 5 | 2019 | 9 | 0.900 |
Why?
| | Antivenins | 5 | 2019 | 35 | 0.890 |
Why?
| | Diphenhydramine | 4 | 2023 | 31 | 0.880 |
Why?
| | Akathisia, Drug-Induced | 2 | 2020 | 6 | 0.870 |
Why?
| | Thiazoles | 4 | 2009 | 118 | 0.850 |
Why?
| | Benzodiazepines | 6 | 2023 | 138 | 0.840 |
Why?
| | Prescription Drug Monitoring Programs | 1 | 2023 | 14 | 0.840 |
Why?
| | Spider Venoms | 4 | 2019 | 11 | 0.830 |
Why?
| | Heart Arrest | 8 | 2018 | 323 | 0.810 |
Why?
| | Middle Aged | 54 | 2022 | 31087 | 0.810 |
Why?
| | Muscarinic Antagonists | 3 | 2023 | 27 | 0.800 |
Why?
| | Young Adult | 30 | 2020 | 12438 | 0.800 |
Why?
| | Lorazepam | 3 | 2023 | 26 | 0.790 |
Why?
| | Decision Support Systems, Clinical | 2 | 2023 | 206 | 0.770 |
Why?
| | Seizures | 6 | 2011 | 402 | 0.760 |
Why?
| | Referral and Consultation | 2 | 2020 | 732 | 0.760 |
Why?
| | Physostigmine | 2 | 2020 | 12 | 0.740 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 2 | 2019 | 339 | 0.740 |
Why?
| | Emergency Treatment | 4 | 2015 | 114 | 0.740 |
Why?
| | Piperazines | 4 | 2009 | 339 | 0.740 |
Why?
| | Black Widow Spider | 4 | 2019 | 9 | 0.730 |
Why?
| | Delirium | 2 | 2020 | 77 | 0.730 |
Why?
| | Medical History Taking | 3 | 2018 | 117 | 0.730 |
Why?
| | Dopamine Uptake Inhibitors | 3 | 2011 | 55 | 0.720 |
Why?
| | Anti-Arrhythmia Agents | 4 | 2014 | 112 | 0.680 |
Why?
| | Abdominal Pain | 2 | 2019 | 142 | 0.680 |
Why?
| | Suicide, Attempted | 5 | 2012 | 356 | 0.680 |
Why?
| | Retrospective Studies | 31 | 2023 | 14532 | 0.660 |
Why?
| | Vasoconstrictor Agents | 4 | 2009 | 127 | 0.660 |
Why?
| | Hospitals, Pediatric | 4 | 2018 | 514 | 0.660 |
Why?
| | Emergency Medical Services | 5 | 2025 | 521 | 0.660 |
Why?
| | Back Pain | 1 | 2020 | 53 | 0.650 |
Why?
| | Free Radical Scavengers | 2 | 2011 | 83 | 0.650 |
Why?
| | Patient Handoff | 1 | 2020 | 32 | 0.640 |
Why?
| | Buprenorphine | 2 | 2020 | 162 | 0.640 |
Why?
| | Haloperidol | 1 | 2019 | 32 | 0.620 |
Why?
| | Ketorolac | 1 | 2019 | 20 | 0.620 |
Why?
| | Social Work | 1 | 2020 | 83 | 0.610 |
Why?
| | Pharmacoepidemiology | 1 | 2018 | 19 | 0.610 |
Why?
| | Tertiary Care Centers | 3 | 2017 | 153 | 0.590 |
Why?
| | Gastric Lavage | 3 | 2009 | 9 | 0.590 |
Why?
| | Colorado | 15 | 2021 | 4403 | 0.590 |
Why?
| | Prospective Studies | 18 | 2023 | 7150 | 0.580 |
Why?
| | Immunoglobulin Fab Fragments | 4 | 2019 | 59 | 0.580 |
Why?
| | Vomiting | 6 | 2019 | 129 | 0.580 |
Why?
| | Substance-Related Disorders | 5 | 2012 | 1022 | 0.580 |
Why?
| | Hypotension | 2 | 2022 | 117 | 0.570 |
Why?
| | Child | 28 | 2023 | 20932 | 0.560 |
Why?
| | Drug Storage | 2 | 2017 | 58 | 0.560 |
Why?
| | Electronic Health Records | 4 | 2024 | 977 | 0.550 |
Why?
| | Accidents, Home | 1 | 2017 | 29 | 0.540 |
Why?
| | Cannabinoids | 3 | 2017 | 154 | 0.540 |
Why?
| | Medical Marijuana | 2 | 2019 | 111 | 0.540 |
Why?
| | Pulmonary Embolism | 3 | 2021 | 212 | 0.540 |
Why?
| | Plant Preparations | 2 | 2015 | 32 | 0.530 |
Why?
| | Fibrin Fibrinogen Degradation Products | 2 | 2007 | 82 | 0.530 |
Why?
| | Calcium Gluconate | 1 | 2016 | 4 | 0.530 |
Why?
| | Hypocalcemia | 1 | 2016 | 26 | 0.520 |
Why?
| | Quaternary Ammonium Compounds | 1 | 2016 | 51 | 0.510 |
Why?
| | Health Records, Personal | 1 | 2016 | 26 | 0.510 |
Why?
| | Nonprescription Drugs | 4 | 2016 | 66 | 0.500 |
Why?
| | Mobile Applications | 1 | 2018 | 166 | 0.500 |
Why?
| | Practice Patterns, Physicians' | 3 | 2023 | 1257 | 0.490 |
Why?
| | Blood Proteins | 1 | 2017 | 244 | 0.490 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2023 | 244 | 0.490 |
Why?
| | Antidepressive Agents | 2 | 2012 | 228 | 0.480 |
Why?
| | Fat Emulsions, Intravenous | 2 | 2014 | 28 | 0.480 |
Why?
| | Liver | 6 | 2022 | 1836 | 0.480 |
Why?
| | Prescription Drug Misuse | 1 | 2015 | 40 | 0.480 |
Why?
| | Treatment Outcome | 18 | 2020 | 10232 | 0.470 |
Why?
| | Electrocardiography | 5 | 2013 | 612 | 0.460 |
Why?
| | Child, Preschool | 13 | 2018 | 10499 | 0.460 |
Why?
| | Infant | 12 | 2018 | 9005 | 0.450 |
Why?
| | Asymptomatic Diseases | 2 | 2013 | 84 | 0.440 |
Why?
| | Observer Variation | 3 | 2010 | 314 | 0.430 |
Why?
| | Crime | 2 | 2011 | 57 | 0.430 |
Why?
| | Adolescent | 27 | 2020 | 20409 | 0.420 |
Why?
| | Adrenergic alpha-2 Receptor Agonists | 1 | 2013 | 25 | 0.420 |
Why?
| | Energy Drinks | 1 | 2013 | 4 | 0.420 |
Why?
| | Performance-Enhancing Substances | 1 | 2013 | 9 | 0.420 |
Why?
| | Arrhythmias, Cardiac | 3 | 2022 | 321 | 0.410 |
Why?
| | Double-Blind Method | 7 | 2020 | 1873 | 0.410 |
Why?
| | Accidents | 1 | 2013 | 38 | 0.410 |
Why?
| | Bradycardia | 1 | 2013 | 53 | 0.410 |
Why?
| | Plasmapheresis | 1 | 2013 | 22 | 0.410 |
Why?
| | Poisons | 2 | 2023 | 20 | 0.410 |
Why?
| | Diet Surveys | 1 | 2013 | 92 | 0.410 |
Why?
| | Amphotericin B | 1 | 2013 | 30 | 0.410 |
Why?
| | Hematemesis | 1 | 2012 | 3 | 0.410 |
Why?
| | beta-Alanine | 1 | 2012 | 16 | 0.400 |
Why?
| | Phytotherapy | 1 | 2013 | 78 | 0.400 |
Why?
| | Aspartate Aminotransferases | 3 | 2010 | 89 | 0.400 |
Why?
| | Stomach Diseases | 1 | 2012 | 19 | 0.400 |
Why?
| | Foreign Bodies | 2 | 2011 | 103 | 0.400 |
Why?
| | Ethers | 1 | 2012 | 16 | 0.400 |
Why?
| | Sulfonylurea Compounds | 2 | 2010 | 45 | 0.400 |
Why?
| | Aged | 27 | 2019 | 22063 | 0.390 |
Why?
| | Citalopram | 1 | 2012 | 30 | 0.390 |
Why?
| | Antithrombins | 1 | 2012 | 58 | 0.390 |
Why?
| | Liver Function Tests | 7 | 2020 | 112 | 0.390 |
Why?
| | Drug Administration Schedule | 5 | 2014 | 763 | 0.380 |
Why?
| | Antifungal Agents | 1 | 2013 | 130 | 0.380 |
Why?
| | Dronabinol | 4 | 2021 | 203 | 0.380 |
Why?
| | Genetic Predisposition to Disease | 1 | 2020 | 2271 | 0.380 |
Why?
| | Propafenone | 1 | 2011 | 2 | 0.380 |
Why?
| | Thiophenes | 1 | 2012 | 117 | 0.380 |
Why?
| | Disease Models, Animal | 9 | 2011 | 4073 | 0.380 |
Why?
| | C-Peptide | 2 | 2010 | 155 | 0.380 |
Why?
| | Alcohol Drinking | 4 | 2012 | 764 | 0.370 |
Why?
| | Opioid-Related Disorders | 2 | 2020 | 484 | 0.370 |
Why?
| | Firesetting Behavior | 1 | 2011 | 1 | 0.370 |
Why?
| | Anaphylaxis | 2 | 2012 | 99 | 0.370 |
Why?
| | Infusions, Intravenous | 6 | 2013 | 402 | 0.370 |
Why?
| | Clinical Enzyme Tests | 2 | 2013 | 10 | 0.370 |
Why?
| | Benzimidazoles | 1 | 2012 | 162 | 0.370 |
Why?
| | Charcoal | 4 | 2006 | 24 | 0.370 |
Why?
| | Temperance | 2 | 2010 | 13 | 0.360 |
Why?
| | Aged, 80 and over | 15 | 2018 | 7052 | 0.360 |
Why?
| | Administration, Intravenous | 4 | 2016 | 142 | 0.360 |
Why?
| | Burns | 2 | 2015 | 292 | 0.360 |
Why?
| | Chemical and Drug Induced Liver Injury, Chronic | 1 | 2011 | 11 | 0.360 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3081 | 0.350 |
Why?
| | Brain Edema | 1 | 2011 | 61 | 0.350 |
Why?
| | Evidence-Based Medicine | 4 | 2023 | 715 | 0.350 |
Why?
| | Cholinergic Antagonists | 1 | 2011 | 29 | 0.350 |
Why?
| | Amitriptyline | 2 | 2001 | 20 | 0.350 |
Why?
| | Self-Injurious Behavior | 1 | 2012 | 124 | 0.350 |
Why?
| | Blood Chemical Analysis | 3 | 2021 | 97 | 0.350 |
Why?
| | Immunologic Factors | 2 | 2019 | 229 | 0.350 |
Why?
| | Tachycardia, Ventricular | 1 | 2012 | 168 | 0.340 |
Why?
| | Time Factors | 12 | 2020 | 6530 | 0.340 |
Why?
| | United States | 18 | 2025 | 13865 | 0.340 |
Why?
| | Population Surveillance | 1 | 2013 | 440 | 0.340 |
Why?
| | Liver Failure | 1 | 2011 | 91 | 0.340 |
Why?
| | Hydrofluoric Acid | 2 | 2016 | 8 | 0.340 |
Why?
| | Pharmaceutical Vehicles | 1 | 2010 | 11 | 0.330 |
Why?
| | Propylene Glycol | 1 | 2010 | 10 | 0.330 |
Why?
| | Barium | 1 | 2009 | 28 | 0.330 |
Why?
| | Explosive Agents | 1 | 2009 | 6 | 0.330 |
Why?
| | Hypokalemia | 1 | 2009 | 24 | 0.330 |
Why?
| | Warfarin | 1 | 2010 | 147 | 0.320 |
Why?
| | Imines | 2 | 2022 | 8 | 0.320 |
Why?
| | Liver Diseases, Alcoholic | 2 | 2007 | 89 | 0.320 |
Why?
| | Cross-Sectional Studies | 9 | 2020 | 5078 | 0.320 |
Why?
| | Iatrogenic Disease | 1 | 2010 | 60 | 0.320 |
Why?
| | Acidosis, Lactic | 1 | 2010 | 46 | 0.320 |
Why?
| | Emetics | 2 | 2006 | 7 | 0.320 |
Why?
| | Deception | 1 | 2009 | 18 | 0.320 |
Why?
| | Random Allocation | 3 | 2007 | 344 | 0.310 |
Why?
| | Surveys and Questionnaires | 4 | 2018 | 5429 | 0.310 |
Why?
| | Risk Factors | 9 | 2017 | 9779 | 0.310 |
Why?
| | Benzoquinones | 2 | 2022 | 48 | 0.310 |
Why?
| | Risk Assessment | 8 | 2017 | 3255 | 0.310 |
Why?
| | Oximetry | 1 | 2009 | 88 | 0.310 |
Why?
| | Length of Stay | 3 | 2020 | 1132 | 0.300 |
Why?
| | Odds Ratio | 7 | 2017 | 1018 | 0.300 |
Why?
| | Fluorides | 2 | 2016 | 50 | 0.300 |
Why?
| | Hypothermia, Induced | 1 | 2009 | 76 | 0.300 |
Why?
| | Point-of-Care Systems | 1 | 2010 | 149 | 0.290 |
Why?
| | Cyanoacrylates | 1 | 2008 | 4 | 0.290 |
Why?
| | Eyelashes | 1 | 2008 | 4 | 0.290 |
Why?
| | Hypoglycemia | 2 | 2010 | 424 | 0.290 |
Why?
| | Intellectual Disability | 1 | 2009 | 145 | 0.290 |
Why?
| | Adhesives | 1 | 2008 | 13 | 0.290 |
Why?
| | Alcoholism | 4 | 2023 | 764 | 0.290 |
Why?
| | Animals | 22 | 2019 | 35334 | 0.290 |
Why?
| | Reference Values | 4 | 2017 | 795 | 0.290 |
Why?
| | Detergents | 1 | 2008 | 44 | 0.290 |
Why?
| | Cardiovascular System | 1 | 2009 | 136 | 0.280 |
Why?
| | Publishing | 1 | 2009 | 140 | 0.280 |
Why?
| | Brugada Syndrome | 1 | 2007 | 9 | 0.280 |
Why?
| | Polyethylene Glycols | 1 | 2012 | 611 | 0.280 |
Why?
| | Niacin | 1 | 2007 | 17 | 0.270 |
Why?
| | Diazepam | 1 | 2007 | 34 | 0.270 |
Why?
| | Clinical Laboratory Techniques | 1 | 2008 | 94 | 0.270 |
Why?
| | Mice, Inbred Strains | 4 | 2009 | 408 | 0.270 |
Why?
| | Vitamin B Complex | 1 | 2007 | 41 | 0.270 |
Why?
| | Specimen Handling | 1 | 2008 | 163 | 0.270 |
Why?
| | Pediatrics | 1 | 2015 | 1068 | 0.260 |
Why?
| | Thromboembolism | 1 | 2007 | 112 | 0.260 |
Why?
| | Brain Infarction | 1 | 2006 | 23 | 0.260 |
Why?
| | Analgesics | 4 | 2017 | 194 | 0.260 |
Why?
| | Hypoxia-Ischemia, Brain | 1 | 2006 | 33 | 0.250 |
Why?
| | Decontamination | 1 | 2006 | 24 | 0.250 |
Why?
| | Nausea | 4 | 2014 | 111 | 0.250 |
Why?
| | Anticoagulants | 1 | 2010 | 637 | 0.250 |
Why?
| | Self Report | 4 | 2021 | 800 | 0.250 |
Why?
| | Amiodarone | 1 | 2005 | 25 | 0.250 |
Why?
| | Age Factors | 7 | 2017 | 3150 | 0.250 |
Why?
| | Randomized Controlled Trials as Topic | 5 | 2012 | 1368 | 0.240 |
Why?
| | Intention | 1 | 2007 | 163 | 0.240 |
Why?
| | Venous Thrombosis | 1 | 2007 | 176 | 0.240 |
Why?
| | Epilepsy | 2 | 2020 | 322 | 0.240 |
Why?
| | Vasospasm, Intracranial | 1 | 2005 | 17 | 0.240 |
Why?
| | Eating | 4 | 2017 | 371 | 0.240 |
Why?
| | Databases, Factual | 1 | 2010 | 1261 | 0.240 |
Why?
| | Sodium Nitrite | 1 | 2005 | 39 | 0.240 |
Why?
| | Drug Utilization | 5 | 2014 | 170 | 0.230 |
Why?
| | Calcium | 3 | 2016 | 1208 | 0.230 |
Why?
| | Acute Kidney Injury | 1 | 2012 | 789 | 0.230 |
Why?
| | Subarachnoid Hemorrhage | 1 | 2005 | 64 | 0.230 |
Why?
| | Education, Medical | 2 | 2021 | 252 | 0.230 |
Why?
| | Diagnostic Imaging | 1 | 2007 | 326 | 0.230 |
Why?
| | Coma | 2 | 2006 | 33 | 0.230 |
Why?
| | Biomarkers | 7 | 2021 | 3968 | 0.220 |
Why?
| | Triage | 2 | 2025 | 206 | 0.220 |
Why?
| | Hypoglycemic Agents | 2 | 2010 | 1219 | 0.220 |
Why?
| | Hospitals, Urban | 5 | 2021 | 135 | 0.220 |
Why?
| | Case-Control Studies | 4 | 2022 | 3383 | 0.210 |
Why?
| | Injections, Intraperitoneal | 4 | 2009 | 112 | 0.210 |
Why?
| | Insulin | 3 | 2019 | 2313 | 0.210 |
Why?
| | Anti-Anxiety Agents | 2 | 2020 | 45 | 0.210 |
Why?
| | Animal Experimentation | 1 | 2003 | 6 | 0.210 |
Why?
| | Glasgow Coma Scale | 1 | 2004 | 165 | 0.210 |
Why?
| | Sensitivity and Specificity | 5 | 2010 | 1842 | 0.210 |
Why?
| | Calcium Chloride | 1 | 2003 | 12 | 0.210 |
Why?
| | Fibrinolytic Agents | 2 | 2021 | 262 | 0.210 |
Why?
| | Hospitals, Teaching | 3 | 2014 | 113 | 0.200 |
Why?
| | Magnesium Sulfate | 1 | 2003 | 17 | 0.200 |
Why?
| | Cardiopulmonary Resuscitation | 3 | 2018 | 235 | 0.200 |
Why?
| | Longevity | 3 | 2009 | 155 | 0.190 |
Why?
| | Documentation | 1 | 2024 | 184 | 0.190 |
Why?
| | Umbilical Cord | 2 | 2021 | 83 | 0.190 |
Why?
| | Placebos | 2 | 2014 | 200 | 0.190 |
Why?
| | Desipramine | 1 | 2001 | 9 | 0.190 |
Why?
| | Logistic Models | 3 | 2017 | 1983 | 0.190 |
Why?
| | Phenylurea Compounds | 1 | 2022 | 88 | 0.190 |
Why?
| | Confidence Intervals | 4 | 2010 | 316 | 0.180 |
Why?
| | Research Design | 3 | 2006 | 1043 | 0.180 |
Why?
| | Opiate Substitution Treatment | 2 | 2020 | 136 | 0.180 |
Why?
| | Severity of Illness Index | 1 | 2009 | 2734 | 0.180 |
Why?
| | Substance Withdrawal Syndrome | 1 | 2023 | 175 | 0.180 |
Why?
| | Narcotic Antagonists | 2 | 2020 | 164 | 0.180 |
Why?
| | Sinus Thrombosis, Intracranial | 1 | 2021 | 20 | 0.180 |
Why?
| | Hyperthermia, Induced | 1 | 2022 | 108 | 0.180 |
Why?
| | Heart Atria | 1 | 2001 | 129 | 0.180 |
Why?
| | Fractures, Bone | 2 | 2017 | 395 | 0.170 |
Why?
| | Acute Disease | 2 | 2019 | 975 | 0.170 |
Why?
| | Myocardial Contraction | 1 | 2001 | 334 | 0.170 |
Why?
| | Immunoglobulin Fragments | 1 | 1999 | 11 | 0.160 |
Why?
| | Lysergic Acid Diethylamide | 1 | 1999 | 2 | 0.160 |
Why?
| | Droperidol | 1 | 1999 | 4 | 0.160 |
Why?
| | Wisconsin | 1 | 2020 | 99 | 0.160 |
Why?
| | Lithium Carbonate | 1 | 1999 | 5 | 0.160 |
Why?
| | Survival Analysis | 4 | 2010 | 1270 | 0.160 |
Why?
| | Serotonin Syndrome | 1 | 1999 | 5 | 0.160 |
Why?
| | Starch | 1 | 2019 | 21 | 0.160 |
Why?
| | Serotonin Receptor Agonists | 1 | 1999 | 28 | 0.160 |
Why?
| | Scorpion Stings | 1 | 1999 | 1 | 0.160 |
Why?
| | Nutritive Value | 1 | 2019 | 36 | 0.160 |
Why?
| | Geriatric Assessment | 2 | 2011 | 205 | 0.160 |
Why?
| | Healthy Volunteers | 2 | 2019 | 199 | 0.160 |
Why?
| | Administration, Oral | 4 | 2019 | 783 | 0.160 |
Why?
| | Thrombocytopenia | 1 | 2021 | 189 | 0.160 |
Why?
| | Ventricular Premature Complexes | 1 | 1999 | 36 | 0.160 |
Why?
| | Community Health Workers | 1 | 2020 | 59 | 0.160 |
Why?
| | Snake Bites | 1 | 1999 | 28 | 0.160 |
Why?
| | Immune System | 1 | 2020 | 174 | 0.160 |
Why?
| | Mass Screening | 1 | 2007 | 1186 | 0.150 |
Why?
| | Metabolome | 1 | 2022 | 338 | 0.150 |
Why?
| | Fallopian Tube Diseases | 1 | 1998 | 5 | 0.150 |
Why?
| | Pregnancy, Tubal | 1 | 1998 | 5 | 0.150 |
Why?
| | Munchausen Syndrome by Proxy | 1 | 1998 | 2 | 0.150 |
Why?
| | Dietary Carbohydrates | 1 | 2019 | 148 | 0.150 |
Why?
| | Abortifacient Agents, Nonsteroidal | 1 | 1998 | 21 | 0.150 |
Why?
| | Cohort Studies | 7 | 2023 | 5423 | 0.150 |
Why?
| | Drug Therapy, Combination | 4 | 2011 | 1037 | 0.150 |
Why?
| | Cannabidiol | 1 | 2020 | 108 | 0.150 |
Why?
| | Plant Extracts | 1 | 2020 | 198 | 0.150 |
Why?
| | Anticonvulsants | 1 | 2020 | 209 | 0.150 |
Why?
| | Chi-Square Distribution | 2 | 2017 | 515 | 0.150 |
Why?
| | Sex Factors | 5 | 2022 | 1966 | 0.150 |
Why?
| | Sulfasalazine | 1 | 1998 | 23 | 0.140 |
Why?
| | Drug Antagonism | 2 | 2009 | 10 | 0.140 |
Why?
| | Out-of-Hospital Cardiac Arrest | 1 | 2018 | 70 | 0.140 |
Why?
| | Faculty, Medical | 1 | 2021 | 268 | 0.140 |
Why?
| | Dietary Fats | 1 | 2019 | 298 | 0.140 |
Why?
| | Genome-Wide Association Study | 2 | 2023 | 1326 | 0.140 |
Why?
| | Dyspnea | 1 | 1999 | 238 | 0.140 |
Why?
| | Drug Interactions | 4 | 2014 | 397 | 0.140 |
Why?
| | Fellowships and Scholarships | 1 | 2021 | 278 | 0.140 |
Why?
| | Gastrointestinal Agents | 1 | 1998 | 60 | 0.140 |
Why?
| | Mice | 8 | 2009 | 16973 | 0.140 |
Why?
| | Methotrexate | 1 | 1998 | 248 | 0.140 |
Why?
| | Continuity of Patient Care | 1 | 2020 | 276 | 0.140 |
Why?
| | Survival Rate | 3 | 2013 | 1870 | 0.140 |
Why?
| | Incidence | 4 | 2013 | 2643 | 0.140 |
Why?
| | Peptide Fragments | 1 | 2021 | 695 | 0.140 |
Why?
| | Simulation Training | 1 | 2018 | 82 | 0.140 |
Why?
| | Ammonium Compounds | 1 | 2016 | 3 | 0.130 |
Why?
| | Energy Intake | 1 | 2019 | 462 | 0.130 |
Why?
| | Hypnotics and Sedatives | 1 | 1998 | 178 | 0.130 |
Why?
| | Pain Management | 2 | 2017 | 330 | 0.130 |
Why?
| | Clinical Trials as Topic | 2 | 2012 | 1001 | 0.130 |
Why?
| | Prenatal Care | 1 | 2019 | 277 | 0.130 |
Why?
| | Cytochrome P-450 CYP2E1 Inhibitors | 1 | 2016 | 2 | 0.130 |
Why?
| | Metabolic Clearance Rate | 2 | 2019 | 115 | 0.130 |
Why?
| | Ventricular Fibrillation | 1 | 2016 | 57 | 0.130 |
Why?
| | Half-Life | 2 | 2019 | 162 | 0.130 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 1950 | 0.120 |
Why?
| | Pharmacovigilance | 1 | 2015 | 21 | 0.120 |
Why?
| | Milk | 1 | 2016 | 122 | 0.120 |
Why?
| | Herniorrhaphy | 1 | 2016 | 56 | 0.120 |
Why?
| | Genetic Variation | 1 | 2020 | 936 | 0.120 |
Why?
| | Pilot Projects | 1 | 2020 | 1594 | 0.120 |
Why?
| | Adverse Drug Reaction Reporting Systems | 1 | 2015 | 74 | 0.120 |
Why?
| | Fatal Outcome | 2 | 2013 | 300 | 0.120 |
Why?
| | Models, Biological | 2 | 2015 | 1717 | 0.120 |
Why?
| | Hemodialysis Units, Hospital | 1 | 1994 | 5 | 0.120 |
Why?
| | Child Behavior | 1 | 2017 | 235 | 0.120 |
Why?
| | Ondansetron | 1 | 2014 | 15 | 0.110 |
Why?
| | Patient Simulation | 1 | 2014 | 34 | 0.110 |
Why?
| | Liver Failure, Acute | 1 | 2015 | 66 | 0.110 |
Why?
| | Hydrocodone | 1 | 2014 | 16 | 0.110 |
Why?
| | Total Quality Management | 1 | 1994 | 60 | 0.110 |
Why?
| | Cytochrome P-450 CYP2D6 | 1 | 2014 | 28 | 0.110 |
Why?
| | Internship and Residency | 2 | 2014 | 1049 | 0.110 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2015 | 89 | 0.110 |
Why?
| | Curriculum | 1 | 2021 | 922 | 0.110 |
Why?
| | Transaminases | 1 | 2014 | 23 | 0.110 |
Why?
| | Oxycodone | 1 | 2014 | 43 | 0.110 |
Why?
| | Physicians | 2 | 2020 | 872 | 0.110 |
Why?
| | Remote Consultation | 1 | 2014 | 46 | 0.110 |
Why?
| | Prognosis | 3 | 2011 | 3772 | 0.110 |
Why?
| | Guanfacine | 1 | 2013 | 4 | 0.110 |
Why?
| | Pregnancy Complications | 1 | 2019 | 493 | 0.110 |
Why?
| | Clonidine | 1 | 2013 | 26 | 0.110 |
Why?
| | Vitamins | 1 | 2015 | 173 | 0.110 |
Why?
| | International Normalized Ratio | 2 | 2011 | 46 | 0.110 |
Why?
| | Acute Pain | 1 | 2014 | 48 | 0.110 |
Why?
| | Cesium | 1 | 2013 | 20 | 0.110 |
Why?
| | Indazoles | 1 | 2014 | 66 | 0.110 |
Why?
| | Food | 1 | 2015 | 155 | 0.110 |
Why?
| | Walking | 1 | 2017 | 491 | 0.100 |
Why?
| | Deoxycholic Acid | 1 | 2013 | 14 | 0.100 |
Why?
| | Canada | 2 | 2025 | 353 | 0.100 |
Why?
| | Lethargy | 1 | 2012 | 4 | 0.100 |
Why?
| | Duloxetine Hydrochloride | 1 | 2012 | 11 | 0.100 |
Why?
| | Dabigatran | 1 | 2012 | 21 | 0.100 |
Why?
| | Pain Measurement | 4 | 2019 | 507 | 0.100 |
Why?
| | Attitude of Health Personnel | 1 | 2020 | 1102 | 0.100 |
Why?
| | Sleep Stages | 1 | 2012 | 45 | 0.100 |
Why?
| | Tachycardia | 1 | 2012 | 57 | 0.100 |
Why?
| | Pyrazoles | 1 | 2016 | 403 | 0.100 |
Why?
| | Chlorides | 1 | 2013 | 139 | 0.100 |
Why?
| | Sulfhydryl Reagents | 1 | 2012 | 12 | 0.100 |
Why?
| | Mycoses | 1 | 2013 | 73 | 0.100 |
Why?
| | Data Collection | 2 | 2013 | 649 | 0.100 |
Why?
| | Marijuana Abuse | 1 | 2015 | 233 | 0.100 |
Why?
| | Dizziness | 1 | 2012 | 80 | 0.100 |
Why?
| | Athletic Performance | 1 | 2013 | 74 | 0.100 |
Why?
| | Sampling Studies | 1 | 2012 | 96 | 0.090 |
Why?
| | Accidental Falls | 2 | 2011 | 169 | 0.090 |
Why?
| | Patient Discharge | 2 | 2016 | 854 | 0.090 |
Why?
| | Arsenicals | 1 | 2012 | 30 | 0.090 |
Why?
| | Magnesium | 2 | 2004 | 154 | 0.090 |
Why?
| | Drug Combinations | 1 | 2013 | 329 | 0.090 |
Why?
| | Information Systems | 1 | 2011 | 61 | 0.090 |
Why?
| | Follow-Up Studies | 3 | 2010 | 4891 | 0.090 |
Why?
| | Sulfides | 1 | 2012 | 95 | 0.090 |
Why?
| | Marijuana Smoking | 1 | 2015 | 247 | 0.090 |
Why?
| | Laparoscopy | 1 | 2016 | 446 | 0.090 |
Why?
| | Arabia | 1 | 2011 | 2 | 0.090 |
Why?
| | Levamisole | 1 | 2011 | 19 | 0.090 |
Why?
| | Hepatic Encephalopathy | 1 | 2011 | 20 | 0.090 |
Why?
| | Structure-Activity Relationship | 1 | 2012 | 548 | 0.090 |
Why?
| | Immunocompromised Host | 1 | 2013 | 199 | 0.090 |
Why?
| | Drug Contamination | 1 | 2011 | 51 | 0.090 |
Why?
| | Molecular Structure | 1 | 2012 | 482 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2015 | 532 | 0.090 |
Why?
| | Universities | 1 | 2013 | 406 | 0.090 |
Why?
| | Pharmacogenetics | 1 | 2012 | 172 | 0.090 |
Why?
| | Glipizide | 1 | 2010 | 6 | 0.080 |
Why?
| | Sports | 1 | 2013 | 225 | 0.080 |
Why?
| | Laboratories, Hospital | 1 | 2010 | 14 | 0.080 |
Why?
| | Hepatitis, Alcoholic | 1 | 2010 | 13 | 0.080 |
Why?
| | Troponin | 1 | 2010 | 50 | 0.080 |
Why?
| | Glyburide | 1 | 2010 | 32 | 0.080 |
Why?
| | Drug Prescriptions | 2 | 2016 | 242 | 0.080 |
Why?
| | Crowding | 1 | 2010 | 35 | 0.080 |
Why?
| | Watchful Waiting | 1 | 2010 | 67 | 0.080 |
Why?
| | Biological Availability | 2 | 2019 | 147 | 0.080 |
Why?
| | Body Weight | 1 | 2014 | 941 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 222 | 0.080 |
Why?
| | Quetiapine Fumarate | 1 | 2009 | 23 | 0.080 |
Why?
| | Dibenzothiazepines | 1 | 2009 | 17 | 0.080 |
Why?
| | Aripiprazole | 1 | 2009 | 17 | 0.080 |
Why?
| | Risperidone | 1 | 2009 | 29 | 0.080 |
Why?
| | Potassium | 1 | 2009 | 144 | 0.080 |
Why?
| | Efficiency, Organizational | 1 | 2010 | 133 | 0.080 |
Why?
| | Dogs | 1 | 2010 | 385 | 0.080 |
Why?
| | Role | 1 | 2009 | 32 | 0.080 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2011 | 203 | 0.080 |
Why?
| | Head Protective Devices | 1 | 2009 | 19 | 0.080 |
Why?
| | Quality Control | 1 | 2009 | 161 | 0.080 |
Why?
| | Renal Dialysis | 1 | 2013 | 423 | 0.080 |
Why?
| | Acidosis | 2 | 2006 | 89 | 0.080 |
Why?
| | Bibliometrics | 1 | 2009 | 53 | 0.080 |
Why?
| | Glutathione | 3 | 2022 | 349 | 0.080 |
Why?
| | Body Temperature | 1 | 2009 | 214 | 0.080 |
Why?
| | Verapamil | 2 | 2014 | 41 | 0.080 |
Why?
| | Diarrhea | 1 | 2009 | 180 | 0.080 |
Why?
| | Workload | 1 | 2010 | 153 | 0.070 |
Why?
| | Quality Indicators, Health Care | 1 | 2011 | 297 | 0.070 |
Why?
| | Health Services Accessibility | 1 | 2015 | 897 | 0.070 |
Why?
| | Skiing | 1 | 2009 | 44 | 0.070 |
Why?
| | Informed Consent | 2 | 2006 | 165 | 0.070 |
Why?
| | Bacitracin | 1 | 2008 | 6 | 0.070 |
Why?
| | Adhesiveness | 1 | 2008 | 20 | 0.070 |
Why?
| | Pharmacy Service, Hospital | 1 | 2009 | 90 | 0.070 |
Why?
| | Acetone | 1 | 2008 | 12 | 0.070 |
Why?
| | Hair Preparations | 1 | 2008 | 7 | 0.070 |
Why?
| | Cause of Death | 1 | 2010 | 395 | 0.070 |
Why?
| | Propylene Glycols | 1 | 2008 | 27 | 0.070 |
Why?
| | Military Personnel | 1 | 2014 | 518 | 0.070 |
Why?
| | Nylons | 1 | 2008 | 20 | 0.070 |
Why?
| | Withholding Treatment | 1 | 2008 | 71 | 0.070 |
Why?
| | Students | 1 | 2013 | 581 | 0.070 |
Why?
| | Equipment Design | 1 | 2009 | 514 | 0.070 |
Why?
| | Glycerol | 1 | 2008 | 92 | 0.070 |
Why?
| | Cellulose | 1 | 2008 | 61 | 0.070 |
Why?
| | Quinolones | 1 | 2009 | 127 | 0.070 |
Why?
| | Substance Abuse Detection | 2 | 2021 | 79 | 0.070 |
Why?
| | Drug Synergism | 1 | 2008 | 370 | 0.070 |
Why?
| | Nephelometry and Turbidimetry | 1 | 2007 | 13 | 0.070 |
Why?
| | Polypharmacy | 1 | 2008 | 82 | 0.070 |
Why?
| | Laboratories | 1 | 2008 | 109 | 0.070 |
Why?
| | Tissue Distribution | 2 | 2019 | 315 | 0.070 |
Why?
| | Research | 2 | 2011 | 419 | 0.070 |
Why?
| | Phosphates | 1 | 2008 | 181 | 0.070 |
Why?
| | Formates | 1 | 2006 | 14 | 0.070 |
Why?
| | Defibrillators | 1 | 2006 | 16 | 0.070 |
Why?
| | Combined Modality Therapy | 1 | 2009 | 1201 | 0.070 |
Why?
| | Methanol | 1 | 2006 | 35 | 0.070 |
Why?
| | Periodicals as Topic | 1 | 2009 | 204 | 0.060 |
Why?
| | Kidney Transplantation | 1 | 2013 | 669 | 0.060 |
Why?
| | Hospitalization | 2 | 2011 | 2076 | 0.060 |
Why?
| | Blindness | 1 | 2006 | 38 | 0.060 |
Why?
| | Vasopressins | 1 | 2006 | 64 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2007 | 422 | 0.060 |
Why?
| | Aging | 2 | 2014 | 1770 | 0.060 |
Why?
| | Probability | 2 | 2010 | 302 | 0.060 |
Why?
| | Respiratory Insufficiency | 1 | 2009 | 312 | 0.060 |
Why?
| | Health Services for the Aged | 1 | 2006 | 72 | 0.060 |
Why?
| | Spinal Diseases | 1 | 2006 | 47 | 0.060 |
Why?
| | Epinephrine | 1 | 2006 | 141 | 0.060 |
Why?
| | Naproxen | 1 | 2006 | 16 | 0.060 |
Why?
| | Ipecac | 1 | 2005 | 8 | 0.060 |
Why?
| | Population Dynamics | 1 | 2006 | 138 | 0.060 |
Why?
| | Telemedicine | 1 | 2014 | 792 | 0.060 |
Why?
| | Haplorhini | 1 | 2005 | 51 | 0.060 |
Why?
| | Hospitals, University | 1 | 2006 | 179 | 0.060 |
Why?
| | Ibuprofen | 1 | 2006 | 81 | 0.060 |
Why?
| | Geriatrics | 1 | 2006 | 81 | 0.060 |
Why?
| | Premedication | 1 | 2005 | 42 | 0.060 |
Why?
| | Respiration, Artificial | 1 | 2009 | 615 | 0.060 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1510 | 0.060 |
Why?
| | Risk | 1 | 2007 | 857 | 0.060 |
Why?
| | Spine | 1 | 2006 | 160 | 0.060 |
Why?
| | Single-Blind Method | 1 | 2005 | 269 | 0.060 |
Why?
| | Water | 1 | 2008 | 442 | 0.060 |
Why?
| | Motivation | 1 | 2009 | 547 | 0.060 |
Why?
| | Blood Glucose | 2 | 2019 | 2071 | 0.060 |
Why?
| | Fluoride Poisoning | 1 | 2004 | 3 | 0.060 |
Why?
| | Resuscitation | 1 | 2006 | 238 | 0.050 |
Why?
| | Phenobarbital | 1 | 2023 | 19 | 0.050 |
Why?
| | Guidelines as Topic | 1 | 2005 | 261 | 0.050 |
Why?
| | Delphi Technique | 1 | 2025 | 227 | 0.050 |
Why?
| | Maltose | 1 | 2023 | 6 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2023 | 3 | 0.050 |
Why?
| | Health Policy | 1 | 2006 | 350 | 0.050 |
Why?
| | Mycophenolic Acid | 1 | 2004 | 110 | 0.050 |
Why?
| | Sheep | 1 | 2006 | 840 | 0.050 |
Why?
| | Urea | 1 | 2023 | 76 | 0.050 |
Why?
| | Survival | 1 | 2003 | 38 | 0.050 |
Why?
| | Pregnancy | 3 | 2021 | 6412 | 0.050 |
Why?
| | Internet | 1 | 2007 | 620 | 0.050 |
Why?
| | Aspirin | 1 | 2006 | 378 | 0.050 |
Why?
| | Patient Participation | 1 | 2006 | 412 | 0.050 |
Why?
| | Lactates | 1 | 2022 | 85 | 0.050 |
Why?
| | Sex Distribution | 2 | 2015 | 359 | 0.050 |
Why?
| | Prevalence | 3 | 2015 | 2561 | 0.050 |
Why?
| | Urban Population | 2 | 2019 | 442 | 0.050 |
Why?
| | Culture Techniques | 1 | 2001 | 81 | 0.050 |
Why?
| | Consensus | 1 | 2025 | 622 | 0.050 |
Why?
| | Blood Physiological Phenomena | 1 | 2021 | 13 | 0.050 |
Why?
| | Neural Conduction | 1 | 2001 | 83 | 0.050 |
Why?
| | Academic Medical Centers | 2 | 2016 | 478 | 0.050 |
Why?
| | Breast Neoplasms | 1 | 2013 | 2101 | 0.040 |
Why?
| | Hirudins | 1 | 2021 | 53 | 0.040 |
Why?
| | Calcium Channel Blockers | 1 | 2001 | 160 | 0.040 |
Why?
| | Controlled Clinical Trials as Topic | 1 | 2020 | 27 | 0.040 |
Why?
| | Infusions, Parenteral | 1 | 2020 | 37 | 0.040 |
Why?
| | Certification | 1 | 2020 | 94 | 0.040 |
Why?
| | Pirenzepine | 1 | 1999 | 7 | 0.040 |
Why?
| | Scorpions | 1 | 1999 | 3 | 0.040 |
Why?
| | Ambulatory Care | 1 | 2023 | 507 | 0.040 |
Why?
| | South America | 1 | 1999 | 58 | 0.040 |
Why?
| | Blood Cell Count | 2 | 2013 | 52 | 0.040 |
Why?
| | Narcotics | 1 | 1999 | 45 | 0.040 |
Why?
| | Temperature | 1 | 2022 | 635 | 0.040 |
Why?
| | Rupture, Spontaneous | 1 | 1998 | 18 | 0.040 |
Why?
| | Postprandial Period | 1 | 2019 | 104 | 0.040 |
Why?
| | Central Nervous System Depressants | 1 | 1999 | 83 | 0.040 |
Why?
| | Manikins | 1 | 2018 | 26 | 0.040 |
Why?
| | Videotape Recording | 1 | 2018 | 34 | 0.040 |
Why?
| | Immunosuppressive Agents | 1 | 2004 | 858 | 0.040 |
Why?
| | Sorption Detoxification | 1 | 1998 | 2 | 0.040 |
Why?
| | Analysis of Variance | 1 | 2001 | 1286 | 0.040 |
Why?
| | Lipids | 1 | 2022 | 614 | 0.040 |
Why?
| | Dietary Proteins | 1 | 2019 | 129 | 0.040 |
Why?
| | North America | 1 | 1999 | 294 | 0.040 |
Why?
| | Cholinesterase Inhibitors | 1 | 1998 | 30 | 0.040 |
Why?
| | Laparotomy | 1 | 1998 | 104 | 0.040 |
Why?
| | Feedback | 1 | 2018 | 162 | 0.040 |
Why?
| | Recombinant Proteins | 1 | 2021 | 1311 | 0.040 |
Why?
| | Cardiomyopathies | 1 | 2001 | 339 | 0.040 |
Why?
| | Maternal Health Services | 1 | 2019 | 92 | 0.030 |
Why?
| | Central Nervous System | 1 | 1999 | 256 | 0.030 |
Why?
| | Cross-Over Studies | 1 | 2019 | 522 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2001 | 851 | 0.030 |
Why?
| | Triglycerides | 1 | 2019 | 514 | 0.030 |
Why?
| | Registries | 2 | 2010 | 1902 | 0.030 |
Why?
| | Socioeconomic Factors | 2 | 2015 | 1211 | 0.030 |
Why?
| | Bipolar Disorder | 1 | 1999 | 235 | 0.030 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1029 | 0.030 |
Why?
| | Hallucinogens | 1 | 2017 | 102 | 0.030 |
Why?
| | Dialysis | 1 | 2015 | 18 | 0.030 |
Why?
| | Centrifugation | 1 | 2015 | 30 | 0.030 |
Why?
| | Tennessee | 1 | 1994 | 42 | 0.030 |
Why?
| | Observation | 1 | 2014 | 51 | 0.030 |
Why?
| | Hematocrit | 1 | 1994 | 92 | 0.030 |
Why?
| | Syndrome | 1 | 2015 | 338 | 0.030 |
Why?
| | Anesthetics, Local | 1 | 2014 | 79 | 0.030 |
Why?
| | International Classification of Diseases | 1 | 2015 | 122 | 0.030 |
Why?
| | Program Evaluation | 1 | 2018 | 873 | 0.030 |
Why?
| | Warfare | 1 | 2014 | 65 | 0.030 |
Why?
| | Erythropoietin | 1 | 1994 | 88 | 0.030 |
Why?
| | Protein Binding | 1 | 2020 | 2121 | 0.030 |
Why?
| | Injections, Intralesional | 1 | 2013 | 33 | 0.030 |
Why?
| | Hospitals, Veterans | 1 | 1994 | 242 | 0.030 |
Why?
| | Salicylates | 1 | 2013 | 30 | 0.030 |
Why?
| | Urinalysis | 1 | 2013 | 75 | 0.030 |
Why?
| | Nursing Staff, Hospital | 1 | 1994 | 149 | 0.020 |
Why?
| | Iron | 1 | 1994 | 283 | 0.020 |
Why?
| | Hemoglobins | 1 | 1994 | 337 | 0.020 |
Why?
| | Long QT Syndrome | 1 | 2013 | 67 | 0.020 |
Why?
| | Therapeutic Irrigation | 1 | 2012 | 78 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 2012 | 66 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 7 | 0.020 |
Why?
| | Agranulocytosis | 1 | 2011 | 30 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 52 | 0.020 |
Why?
| | Computer Simulation | 1 | 2015 | 937 | 0.020 |
Why?
| | Cytochrome P-450 Enzyme System | 1 | 2012 | 151 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2019 | 1168 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 20 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2012 | 133 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 131 | 0.020 |
Why?
| | Toothache | 1 | 2010 | 5 | 0.020 |
Why?
| | Models, Theoretical | 1 | 1994 | 548 | 0.020 |
Why?
| | Quality of Health Care | 1 | 2015 | 607 | 0.020 |
Why?
| | Disease Outbreaks | 1 | 2014 | 349 | 0.020 |
Why?
| | Immunoassay | 1 | 2011 | 108 | 0.020 |
Why?
| | Drug Administration Routes | 1 | 2010 | 37 | 0.020 |
Why?
| | Insurance Coverage | 1 | 2012 | 219 | 0.020 |
Why?
| | Injections, Intravenous | 1 | 2010 | 202 | 0.020 |
Why?
| | Neurologic Examination | 1 | 2010 | 112 | 0.020 |
Why?
| | Patient Education as Topic | 1 | 1994 | 738 | 0.020 |
Why?
| | Age Distribution | 1 | 2010 | 371 | 0.020 |
Why?
| | Intestines | 1 | 2012 | 350 | 0.020 |
Why?
| | Kidney Failure, Chronic | 1 | 1994 | 546 | 0.020 |
Why?
| | Polymorphism, Genetic | 1 | 2012 | 636 | 0.020 |
Why?
| | Safety | 1 | 2010 | 335 | 0.020 |
Why?
| | Precision Medicine | 1 | 2012 | 385 | 0.020 |
Why?
| | Ethanol | 1 | 2012 | 591 | 0.020 |
Why?
| | Regression Analysis | 1 | 2010 | 994 | 0.020 |
Why?
| | Seasons | 1 | 2010 | 492 | 0.020 |
Why?
| | Clinical Competence | 1 | 2014 | 1015 | 0.020 |
Why?
| | Disease Management | 1 | 2011 | 591 | 0.020 |
Why?
| | Bilirubin | 1 | 2007 | 95 | 0.020 |
Why?
| | Pulse | 1 | 2006 | 23 | 0.020 |
Why?
| | Genotype | 1 | 2012 | 1827 | 0.020 |
Why?
| | Metabolomics | 1 | 2012 | 652 | 0.020 |
Why?
| | Blastomycosis | 1 | 2006 | 10 | 0.020 |
Why?
| | Contraindications | 1 | 2006 | 89 | 0.020 |
Why?
| | Amyloidosis | 1 | 2006 | 42 | 0.020 |
Why?
| | Coronary Circulation | 1 | 2006 | 138 | 0.020 |
Why?
| | Biopsy, Fine-Needle | 1 | 2006 | 67 | 0.020 |
Why?
| | Electric Countershock | 1 | 2006 | 105 | 0.020 |
Why?
| | European Union | 1 | 2005 | 10 | 0.020 |
Why?
| | Fever | 1 | 2007 | 298 | 0.020 |
Why?
| | Disaster Planning | 1 | 2006 | 83 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2007 | 5769 | 0.020 |
Why?
| | Emergencies | 1 | 2006 | 156 | 0.020 |
Why?
| | Administration, Inhalation | 1 | 2006 | 673 | 0.010 |
Why?
| | United States Food and Drug Administration | 1 | 2005 | 195 | 0.010 |
Why?
| | Up-Regulation | 1 | 2007 | 832 | 0.010 |
Why?
| | Renal Insufficiency | 1 | 2006 | 149 | 0.010 |
Why?
| | Pharmaceutical Preparations | 1 | 2006 | 168 | 0.010 |
Why?
| | Swine | 1 | 2006 | 760 | 0.010 |
Why?
| | Brain Injuries | 1 | 2009 | 469 | 0.010 |
Why?
| | Mice, Inbred ICR | 1 | 2004 | 111 | 0.010 |
Why?
| | Lupus Nephritis | 1 | 2004 | 49 | 0.010 |
Why?
| | Phenotype | 1 | 2012 | 3058 | 0.010 |
Why?
| | In Vitro Techniques | 1 | 2004 | 1091 | 0.010 |
Why?
| | Papillary Muscles | 1 | 2001 | 14 | 0.010 |
Why?
| | Models, Cardiovascular | 1 | 2001 | 192 | 0.010 |
Why?
| | Miosis | 1 | 1999 | 3 | 0.010 |
Why?
| | Pupil | 1 | 1999 | 13 | 0.010 |
Why?
| | Blood Pressure | 1 | 2006 | 1735 | 0.010 |
Why?
| | Hemodynamics | 1 | 2004 | 1094 | 0.010 |
Why?
| | Chronic Disease | 1 | 2004 | 1722 | 0.010 |
Why?
| | Algorithms | 1 | 2004 | 1614 | 0.010 |
Why?
| | Rats, Sprague-Dawley | 1 | 2001 | 2393 | 0.010 |
Why?
| | Rats | 1 | 2001 | 5470 | 0.010 |
Why?
| | Neoplasms | 1 | 2006 | 2450 | 0.010 |
Why?
|
|
Heard's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|